Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01850615 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 323
- Enrollment target
NCT01850615 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 323 participants.
The verdict
NCT01850615, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 323 participants
- Enrollment target
Study Summary
This trial is conducted in Asia, Europe, South America, and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of FIAsp in a basal-bolus regimen versus basal insulin therapy, both in combination with metformin in adult subjects with type 2 diabetes.
Interventions
- DRUG Faster-acting insulin aspart
- DRUG basal insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2013-09-23 |
| Est. Completion | 2014-11-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01850615
The ClinicalTrials.gov registry entry for NCT01850615 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 323 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Faster-acting insulin aspart is the first listed.
NCT01850615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01850615 about?
NCT01850615 is a clinical study titled "Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes". This trial is conducted in Asia, Europe, South America, and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of FIAsp in a basal-bolus regimen versus basal insulin therapy, both in combination with metformin in adult subjects with type 2 diabetes.
What is the current status of trial NCT01850615?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 323 participants. The study started on 2013-09-23. Estimated completion is 2014-11-17.
What interventions are being tested in trial NCT01850615?
The interventions under investigation include: Faster-acting insulin aspart (DRUG), basal insulin (DRUG).
Who is sponsoring clinical trial NCT01850615?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.